Nivolumab plus Ipilimumab Improves PFS Over Chemotherapy Among Previously Untreated Patients with MSI-H or dMMR mCRC By Ogkologos - December 9, 2024 790 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 8HW study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Addressing Racial Disparities in Cancer Care: “Your Stories” Podcast May 12, 2022 This Harmful Chemical Is Still Being Used In Popular Household Products June 15, 2021 After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms April 11, 2019 Boy Born With Heart Defect Gets Surgery To Help It Triple... December 26, 2021 Load more HOT NEWS Long-Term Follow-Up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options... Cancer in children and young people: how far we’ve come Get the Most out of Seasonal Fruits! Women at High Risk of Breast Cancer Find it Hard to...
